BridgeMD
Safety and efficacy of olanzapine treatment in psychosis: Effect of genetic and epigenetic factors – covariates of treatment response
EU CTIS ID: 2022-502902-33-00
What this study is testing
The primary aim is to evaluate proportions (frequency) of gene polymorphisms in CYP1A2, MDR1, 5HT2A, 5HT2C, HDAC3 and HDAC4 genes in the study population of patients with schizophrenia.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age 18‒60 years
- Dg. F20 (schizophrenia) or F25 (schizoaffective disorders) according to ICD-10
- Established treatment with olanzapine, or planned initiation of olanzapine treatment
- Expressed the informed consent and will to co-operate
- Women of childbearing potential can be included only if they are using at least an acceptable effective contraceptive measure (Chapter 8.10)
You likely can't join if
- Sui juris restriction or divestiture
- Olanzapine or caffeine contraindication
- Pregnancy, or planning to conceive, breastfeeding
- Prior participation in any other trial involving investigational medication or medical devices within 14 days prior to the enrolment and during this trial
- Other serious medical or psychiatric illness that is not adequately controlled and, in the investigator’s opinion, would not permit the subject to be managed according to the protocol
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.